Form 4: Shattuck Labs Officer Acquires Shares & Warrants in Private Placement

Shattuck Labs' General Counsel, Stephen Stout, acquired 12,805 common shares and warrants in a private placement at $0.8677 per unit.

Summary

• Stephen Stout, General Counsel, Corporate Secretary, and Chief Ethics and Compliance Officer of Shattuck Labs, Inc. (STTK), acquired 12,805 shares of common stock and 12,805 accompanying warrants.
• The acquisition was part of a private placement, which closed on August 25, 2025, pursuant to a securities purchase agreement dated August 4, 2025.
• The combined price per share and accompanying warrant was $0.8677.
• Following this transaction, Stephen Stout beneficially owns 86,275 shares of common stock and 12,805 warrants.
• The warrants are exercisable at $1.0846 per share.

Sentiment

Score: 7

Explanation: The insider purchase indicates confidence, and the capital raise supports ongoing operations, but dilution and the future-dated nature of the transaction (as reported) introduce some uncertainty.

Positives

• An officer's participation in a private placement can signal management confidence in the company's future prospects.
• The private placement provides capital to the company.

Negatives

• The issuance of new shares and warrants in a private placement can lead to dilution for existing shareholders.

Risks

• The exercisability of the warrants is contingent on the public announcement of specific Phase 1 clinical trial data for SL-325 (including receptor occupancy and safety data) and the design of planned Phase 2 clinical trials, introducing a dependency on clinical development milestones.

Future Outlook

The exercisability of the warrants is tied to the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety, and the design of planned Phase 2 clinical trials. This indicates a future milestone for the company's drug development pipeline.

Management Comments

• Stephen Stout holds the titles of General Counsel, Corporate Secretary, and Chief Ethics and Compliance Officer.

Industry Context

Private placements are a common method for biotechnology companies like Shattuck Labs to raise capital, especially to fund ongoing research and development, such as clinical trials for drug candidates like SL-325. Insider participation can be viewed positively by the market.

Comparison to Industry Standards

• Private placements are a standard capital-raising tool for early to mid-stage biotechnology companies, often used to fund ongoing research and development, including clinical trials.
• Insider participation in such offerings, as demonstrated by Stephen Stout's acquisition, is a common signal of management confidence in the company's future prospects, aligning with practices observed across the biotech sector.
• The inclusion of warrants alongside common stock in a private placement is a frequent structure in the industry, designed to provide additional upside potential for investors while securing capital for the issuer.

Related Party Transactions

• Stephen Stout, an officer of Shattuck Labs, Inc., participated in the private placement, making this a related party transaction.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and future warrant exercises. However, insider participation may signal confidence.
• Company: Receives capital from the private placement to fund operations and clinical development.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data.
• Public announcement of the design of the planned Phase 2 clinical trial(s) for SL-325.
• Potential exercise of warrants by Stephen Stout and other investors once the exercise conditions are met.

Key Dates

Recommendation

While insider buying can signal confidence, the transaction itself is a capital raise that involves dilution. The future-dated nature of the transaction (as reported in the filing) and the contingent nature of warrant exercisability on future clinical trial data introduce elements of uncertainty. Investors should hold and monitor the company's clinical trial progress for SL-325 and subsequent financial reports.

Keywords

Shattuck Labs, STTK, Stephen Stout, Form 4, Private Placement, Common Stock, Warrants, Insider Trading, Biotechnology, Clinical Trials, SL-325, Capital Raise